Table 1

Characteristics of DISCOVER study patients aged ≥65 years, according to HbA1c level after 12 months of follow-up

Overall
n=2578
HbA1c level after 12 months of follow-up
HbA1c <7.0% n=1398HbA1c ≥7.0% n=1180P value*
Sex, male, n (%)1422 (55.2)788 (56.4) 634 (53.8)0.188
 Missing, n31 2
Age, years, mean (SD)72.2 (5.5)72.4 (5.5) 71.9 (5.5)0.042
HbA1c level at baseline, %, mean (SD)7.8 (1.3)7.4 (1.2) 8.3 (1.3)<0.001
BMI, kg/m2, mean (SD)24.6 (4.3)24.4 (4.3) 25.1 (4.2)0.018
 Missing, n1777884 893
Country GNI, n
 Lower-middle298114 184<0.001
 Upper-middle453217 236<0.001
 High18271067 760<0.001
Time since diagnosis, years, mean (SD)7.8 (6.4)7.4 (6.2) 8.3 (6.4)<0.001
 Missing, n10966 43
Medical history, n (%)
 Macrovascular complications676 (26.3)370 (26.6) 306 (26.0)0.712
 Missing, n108 2
 Microvascular complications759 (29.5)406 (29.1) 353 (29.9)0.661
 Missing, n44
 Chronic kidney disease323 (12.5)192 (13.8) 131 (11.1)0.041
 Missing, n44 0
First-line treatment†, n (%)
 Metformin1699 (65.9)872 (62.4) 827 (70.1)<0.001
 DPP-4 inhibitors559 (21.7)309 (22.1) 250 (21.2)0.573
 Sulfonylureas488 (18.9)204 (14.6) 284 (24.1)<0.001
 α-glucosidase inhibitors85 (3.3)58 (4.1) 27 (2.3)0.008
 Meglitinides62 (2.4)31 (2.2) 31 (2.6)0.498
 SGLT-2 inhibitors26 (1.0)13 (0.9) 13 (1.1)0.663
 Thiazolidinediones60 (2.3)35 (2.5) 25 (2.1)0.518
Treatment at 12 months†, n (%)
 Metformin1680 (66.7)866 (63.0) 814 (71.3)<0.001
 DPP-4 inhibitors1514 (60.2)861 (62.6) 653 (57.2)0.005
 Sulfonylureas889 (35.3)405 (29.5) 484 (42.4)<0.001
 α-glucosidase inhibitors145 (5.8)89 (6.5) 56 (4.9)0.092
 GLP-1 receptor agonists68 (2.7)41 (3.0) 27 (2.4)0.341
 Meglitinides143 (5.7)73 (5.3) 70 (6.1)0.375
 SGLT-2 inhibitors259 (10.3)134 (9.7) 125 (10.9)0.323
 Thiazolidinediones242 (9.6)134 (9.7) 108 (9.5)0.806
 Insulin157 (6.2)32 (2.3) 125 (10.9)<0.001
 Missing6123 38
  • Percentages were calculated for all patients with data available; patients with missing data were excluded.

  • *P value was calculated using Student’s t-test.

  • †Treatment categories are not mutually exclusive, and each category includes monotherapies and combination therapies.

  • BMI, body mass index; DPP-4, dipeptidyl peptidase-4; GLP-1, glucagon-like peptide-1; GNI, gross national income; HbA1c, glycated hemoglobin; SGLT-2, sodium glucose cotransporter 2.